SMA News Today Home | SMA News Today
Jan 17, 2025 · US, EU regulators to review higher-dose Spinraza for use in SMA. Regulators in the U.S. and the European Union have agreed to review Biogen’s applications seeking approval of a higher dose of Spinraza (nusinersen) for all types of spinal muscular atrophy (SMA) in individuals of all ages — a regimen the therapy’s developer …
Zolgensma most successful in presymptomatic SMA infants: Study
Nov 8, 2024 · Zolgensma delivers working copies of SMN1 to body’s cells. Zolgensma (onasemnogene abeparvovec-xioi) is a one-time gene therapy that delivers working copies of SMN1 to the body’s cells so that functional SMN protein can be produced.. In the current study, researchers from Germany, Austria, and Switzerland examined real-world data from 343 SMA patients treated with Zolgensma, including ...
Spinal Muscular Atrophy: Nutrition and Supplementation
The nutritional management of patients with progressive neuromuscular diseases like Spinal Muscular Atrophy (SMA) is complex and is achieved optimally with an individualized approach from a multidisciplinary care team. 1,2 Patients with SMA need nutritional monitoring at least annually with assessment of caloric intake and standard anthropomorphic measurements. 3 In younger children, a ...
Unique BICD2 mutation causes severe SMA-LED: Case study
Dec 4, 2024 · The case study, “ A Novel De Novo Splice Acceptor Variant in BICD2 Is Associated With Spinal Muscular Atrophy,” was published in the American Journal of Medical Genetics. SMA is marked by the degeneration of motor neurons, the nerve cells that control muscle movement, which causes symptoms such as muscle weakness and wasting (atrophy).. SMA-LED is a rare form of SMA caused by mutations in ...
SMA life expectancy by disease type - SMA News Today
3 days ago · SMA type 4 life expectancy. SMA type 4 is the mildest form of the disease and one of the rarest, affecting fewer than 1% of everyone living with SMA. Type 4 symptoms often begin in adulthood, usually after the age of 35. Life expectancy with SMA type 4 is normal.
DMTs have transformed SMA type 1 in Italy, nationwide study finds
Dec 20, 2024 · First DMTs approved for SMA in 2016, have changed disease course. SMA type 1 is the most common type of SMA, accounting for about 60% of cases.It’s also one of the most severe forms, with symptoms apparent at birth or developing within the first six months of life. Without treatment, children with SMA type 1 are generally unable to roll over or sit up unsupported, and most die before age 2 ...
SMA breathing difficulties eased with Zolgensma in real-world study
Dec 4, 2024 · Daily ventilation time for Zolgensma-treated children dropped by 3 hours. SMA is caused primarily by mutations in the SMN1 gene, which contains the genetic code for the protein SMN. These mutations lead to the progressive loss of motor neurons, the specialized nerve cells that control voluntary movement in the body, leading to muscle weakness and wasting.
Specialized equipment for spinal muscular atrophy - SMA News …
Feb 6, 2023 · Wheelchairs are mobile chairs, either manual or powered, for people with spinal muscular atrophy (SMA). Wheelchairs can be pushed by a caregiver or rolled by the person with SMA. Power chairs can be controlled with a joystick, a head array or chin control, and offer options such as postural realignment, and pressure relief.
Rio Landa: Voicing concerns and asking questions in SMA care
Rio Landa: Voicing concerns and asking questions in SMA care. Rio Landa, physician whose 14-year-old son, Mateo, is diagnosed with spinal muscular atrophy (SMA) type 2, describes her approach on seeking second opinions or voicing concerns about changes in …
SMA Type 2: Symptoms, Treatment, and More - SMA News Today
Feb 2, 2023 · Type 2 is an intermediate form of spinal muscular atrophy (SMA), a rare genetic disease characterized by the progressive loss of motor neurons — the nerve cells controlling voluntary movement — that leads to muscle weakness and wasting. This SMA form, one of five main types, manifests in infancy.